Drugs by condition
Drugs approved for lymphoma (non-hodgkin)
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
33
Still marketed, NDA or BLA
Drug classes
11
Novel drugs
18
New molecular entities and new biologics
In development
40+
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for lymphoma (non-hodgkin).
- Oxderys (Doxorubicin Hydrochloride) · Avyxa Holdings Nov 9, 2026
- Beqalzi (Sonrotoclax) · Beone Medicines USA NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMay 13, 2026
- Gobarden (Bendamustine Hydrochloride) · Avyxa Holdings Jul 3, 2025
- Brukinsa (Zanubrutinib) · Beone Medicines USA Accelerated approvalOrphanJun 10, 2025
- Bortezomib (Bortezomib) · Shilpa Aug 26, 2024
All approved drugs for lymphoma (non-hodgkin), by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 58 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Kinase Inhibitor (5)
Proteasome Inhibitor (3)
- Velcade Bortezomib · Takeda Pharms USA · 2003
- Bortezomib Bortezomib · Shilpa · 2024
- Bortezomib Bortezomib · Hospira · 2022
Bispecific CD20-directed CD3 T Cell Engager (2)
CD20-directed Cytolytic Antibody (2)
Programmed Death Receptor-1 Blocking Antibody (1)
- Keytruda Pembrolizumab · Merck Sharp Dohme · 2014
CD30-directed Immunoconjugate (1)
- Adcetris Brentuximab Vedotin · Seattle Genetics · 2011
Thalidomide Analog (1)
- Revlimid Lenalidomide · Bristol Myers Squibb · 2005
Alkylating Drug (1)
- Leukeran Chlorambucil · Waylis Therap · 1957
Folate Analog Metabolic Inhibitor (1)
- Jylamvo Methotrexate · Shorla · 2022
Endoglycosidase (1)
- Rituxan Hycela Rituximab, Hyaluronidase (Human Recombinant) · Genentech INC · 2017
Class not listed in FDA's data (15)
- Beqalzi Sonrotoclax · Beone Medicines USA · 2026
- Lunsumio Velo Mosunetuzumab-Axgb · Genentech INC · 2022
- Zynlonta Loncastuximab Tesirine-Lpyl · Adc Therapeutics SA · 2021
- Monjuvi Tafasitamab-Cxix · Morphosys US INC · 2020
- Polivy Polatuzumab Vedotin-Piiq · Genentech · 2019
- Treanda Bendamustine Hydrochloride · Cephalon · 2008
- Oxderys Doxorubicin Hydrochloride · Avyxa Holdings · 2026
- Gobarden Bendamustine Hydrochloride · Avyxa Holdings · 2025
- Bendamustine Hydrochloride Bendamustine Hydrochloride · Baxter Hlthcare Corp · 2022
- Vivimusta Bendamustine Hydrochloride · Azurity · 2022
- Bendamustine Hydrochloride Bendamustine Hydrochloride · Apotex · 2022
- Belrapzo Bendamustine Hydrochloride · Eagle Pharms · 2018
- Bendeka Bendamustine Hydrochloride · Eagle Pharms · 2015
- Doxorubicin Hydrochloride Doxorubicin Hydrochloride · Pfizer · 1987
- Methotrexate Preservative Free Methotrexate Sodium · Hospira · 1959
Drugs in development for lymphoma (non-hodgkin)
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- OrelabrutinibICP-022Phase 311 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Mantle Cell Lymphoma, Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- APG-2575lisaftoclaxPhase 310 trials
Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- SurovatamigAZD0486, TNB-486Phase 39 trials
AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- BirelentinibDZD8586Phase 37 trials
Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)
- CC-99282BMS-986369, GolcadomidePhase 37 trials
Bristol Myers Squibb · Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma
- OdronextamabREGN1979, OrdsponoPhase 37 trials
Regeneron · Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed/Refractory Follicular Lymphoma
- XNW5004EZH2iPhase 37 trials
Evopoint Biosciences Inc. · Relapsed/Refractory Peripheral T Cell Lymphoma, Advanced Prostate Cancer, Follicular Lymphoma, Grade 1
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- NemtabrutinibMK-1026, ARQ 531Phase 36 trials
Merck & Co. · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
- RocbrutinibLP-168, NWP-775Phase 36 trials
Guangzhou Lupeng Pharmaceutical Company LTD. · Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma
- SCTB41Phase 36 trials
Sinocelltech Ltd. · NHL - Non-Hodgkin's Lymphoma, NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Malignant Solid Tumor
- TacabrutidegBGB-16673Phase 36 trials
BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma
- AbexinostatPCI-24781Phase 35 trials
Xynomic Pharmaceuticals, Inc. · Lymphoma, Follicular, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma
- ICP-248MesutoclaxPhase 35 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Relapsed or Refractory Mantle Cell Lymphoma (MCL), Acute Myeloblastic Leukemia, Relapsed/Refractory Marginal Zone Lymphoma (MZL)
3 discontinued brand-name drugs whose label still names it
- Tazverik Tazemetostat Hydrobromide
- Brukinsa Zanubrutinib
- Bortezomib Bortezomib
More on lymphoma (non-hodgkin): recruiting trials · published research
Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease · Hemophilia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.